IMMUNITYBIO INC (IBRX)
US45256X1037 - Common Stock
IBRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. IBRX has a bad profitability rating. Also its financial health evaluation is rather negative. IBRX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year IBRX has reported negative net income.
In the past year IBRX has reported a negative cash flow from operations.
IBRX had negative earnings in each of the past 5 years.
In the past 5 years IBRX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -161.23%, IBRX is not doing good in the industry: 86.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.23% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IBRX has more shares outstanding
IBRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IBRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -14.60, we must say that IBRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -14.60, IBRX is not doing good in the industry: 81.24% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.6 |
ROIC/WACCN/A
WACC11.53%
2.3 Liquidity
A Current Ratio of 2.68 indicates that IBRX has no problem at all paying its short term obligations.
IBRX's Current ratio of 2.68 is on the low side compared to the rest of the industry. IBRX is outperformed by 68.85% of its industry peers.
IBRX has a Quick Ratio of 2.64. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IBRX (2.64) is worse than 68.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.14% over the past year.
The Revenue has grown by 1228.26% in the past year. This is a very strong growth!
The Revenue has been growing by 65.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)17.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
Revenue 1Y (TTM)1228.26%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Sales Q2Q%7346.34%
3.2 Future
Based on estimates for the next years, IBRX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.45% on average per year.
The Revenue is expected to grow by 411.09% on average over the next years. This is a very strong growth
EPS Next Y24.78%
EPS Next 2Y17.99%
EPS Next 3Y16.92%
EPS Next 5Y32.45%
Revenue Next Year3039.76%
Revenue Next 2Y1549.13%
Revenue Next 3Y710.51%
Revenue Next 5Y411.09%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IBRX's earnings are expected to grow with 16.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.99%
EPS Next 3Y16.92%
5. Dividend
5.1 Amount
No dividends for IBRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUNITYBIO INC
NASDAQ:IBRX (12/20/2024, 8:17:44 PM)
After market: 2.6499 +0.03 (+1.14%)2.62
-0.05 (-1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners9.08%
Inst Owner Change11.55%
Ins Owners5.62%
Ins Owner Change0.04%
Market Cap1.91B
Analysts82.22
Price Target14.54 (454.96%)
Short Float %31.15%
Short Ratio7.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.65%
Min EPS beat(2)-15.34%
Max EPS beat(2)34.64%
EPS beat(4)1
Avg EPS beat(4)-23.47%
Min EPS beat(4)-90.63%
Max EPS beat(4)34.64%
EPS beat(8)3
Avg EPS beat(8)-14.85%
EPS beat(12)4
Avg EPS beat(12)-13.29%
EPS beat(16)5
Avg EPS beat(16)-16.8%
Revenue beat(2)1
Avg Revenue beat(2)22.65%
Min Revenue beat(2)-59.26%
Max Revenue beat(2)104.56%
Revenue beat(4)3
Avg Revenue beat(4)136.81%
Min Revenue beat(4)-59.26%
Max Revenue beat(4)445.1%
Revenue beat(8)7
Avg Revenue beat(8)289.49%
Revenue beat(12)10
Avg Revenue beat(12)342.66%
Revenue beat(16)13
Avg Revenue beat(16)305.53%
PT rev (1m)123.53%
PT rev (3m)123.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.33%
EPS NY rev (1m)-1.63%
EPS NY rev (3m)3.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-60.2%
Revenue NY rev (1m)57.26%
Revenue NY rev (3m)9.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 260.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.01
BVpS-1.02
TBVpS-1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.23% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 70.81% | ||
| Cap/Sales | 173.65% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.64 | ||
| Altman-Z | -14.6 |
F-Score4
WACC11.53%
ROIC/WACCN/A
Cap/Depr(3y)315.06%
Cap/Depr(5y)197.77%
Cap/Sales(3y)16646%
Cap/Sales(5y)10081.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
EPS Next Y24.78%
EPS Next 2Y17.99%
EPS Next 3Y16.92%
EPS Next 5Y32.45%
Revenue 1Y (TTM)1228.26%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Sales Q2Q%7346.34%
Revenue Next Year3039.76%
Revenue Next 2Y1549.13%
Revenue Next 3Y710.51%
Revenue Next 5Y411.09%
EBIT growth 1Y0.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.33%
OCF growth 3YN/A
OCF growth 5YN/A